Immunologic targeting of tumor-specific gene mutations may allow precise eradication of neoplastic cells without toxicity. Epidermal growth factor receptor variant III (EGFRvIII) is a constitutively activated and immunogenic mutation not expressed in normal tissues but widely expressed in glioblastoma multiforme (GBM) and other neoplasms.
INTRODUCTION
Glioblastoma multiforme (GBM), the most common primary malignant neoplasm of the CNS, remains universally fatal. Patients with newly diagnosed GBM have a median overall survival (OS) of only 14.6 months despite maximal surgical resection,conformalradiation, 1 andsystemicchemotherapy.
2 These conventional modalities lack specificity and, as a result, are limited by damage to normal tissue. 1 Immunologic recognition of tumor-specific mutations, however, holds the promise of more precisely eliminating neoplastic cells.
The mutated epidermal growth factor receptor variant III (EGFRvIII) is a cell surface protein containing a tumor-specific epitope reportedly expressed on approximately one third of GBMs 3,4 and a broad array of neoplasms in other tissues, including the breast, lung, and head and neck. [5] [6] [7] [8] It is not found in any normal tissues. 9 EGFRvIII is characterized by a consistent in-frame deletion of 801 base pairs from the extracellular domain that splits a codon and produces a novel glycine at the fusion junction and approximates two normally distant parts of the protein. This mutation encodes a protein with a constitutively active tyrosine kinase 10 that enhances tumorigenicity 11, 12 and tumor cell migration 13 and confers radiation and chemotherapeutic resistance to tumor cells. [14] [15] [16] For patients with GBM who survive 1 year or longer after diagnosis, the expression of EGFRvIII is also an independent negative prognostic indicator of survival. 4 Thus, several factors make EGFRvIII an ideal target for antitumor immunotherapy.
On the basis of preclinical data supporting the safety and potential efficacy of an EGFRvIII-targeted vaccine, 17,18 a phase II, multicenter, prospective trial was undertaken to assess the immunogenicity of an EGFRvIII-targeted peptide vaccine and to estimate progression-free survival (PFS) from vaccination and histologic diagnosis in patients newly diagnosed with GBM who expressed EGFRvIII.
PATIENTS AND METHODS

Vaccine Product
PEPvIII (LEEKKGNYVVTDHC) is a 13-amino-acid peptide with an additional terminal cysteine that spans the EGFRvIII mutation (AnaSpec, San Jose, CA). The peptide preparation was Ͼ 95% pure as assessed by highpressure liquid chromatography and was conjugated to keyhole limpet hemocyanin (KLH; biosyn, Carlsbad, CA) at a 1:1 ratio (w/w) (PEPvIII-KLH) using the heterobifunctional cross-linker sulfosuccinimidyl 6-[3Ј(2-pyridyldithio)-propionamido]hexanoate (Pierce, Rockford, IL).
Patient Selection
Adults with newly diagnosed EGFRvIII-expressing GBM with a gross total resection (Ͼ 95%) and a Karnofsky performance status (KPS) Ն 80% who had no radiographic evidence of progression after standard of care external beam radiation therapy and concurrent temozolomide (TMZ) and were willing to sign an informed consent were eligible for vaccination. The trial was approved by the US Food and Drug Administration (BB-IND-9944) and the local institutional review boards at Duke University Medical Center and M. D. Anderson Cancer Center.
Clinical Protocol
The initial three vaccinations of PEPvIII-KLH were given every two weeks starting 4 weeks after the completion of radiation. Subsequent vaccines were given once a month until radiographic evidence of tumor progression or death. All vaccines were given intradermally in the inguinal region within 10 cm of the inguinal ligament on alternating sides.
Patients were monitored once a month by physical examination and every two months by magnetic resonance imaging. Progressive disease was defined radiographically according to the MacDonald criteria 19 or by the development of a new contrast-enhancing lesion of Ͼ 1 cm at the discretion of the treating neurooncologist. On tumor progression, further treatment was at the discretion of the patient's treating neurooncologist.
Immunologic Monitoring and Immunohistochemical Analysis
Delayed-type hypersensitivity (DTH) testing for cellular immune responses to PEPvIII (1 mg/mL), as well as to the recall antigens tetanus toxoid (NDC 49281-800-83 undiluted; Aventis Pasteur, Swiftwater, PA), Candida (#M15 1:1000; Greer Laboratories, Lenoir, NC), and Trichophyton (#M26, 1:1000; Greer), was performed by using standard intradermal injections in a volume of 100 L. A positive skin test for all antigens was defined as Ͼ 5 mm induration within 48 to 72 hours.
Serum for assessing humoral responses was stored at Ϫ20°C before analysis in an enzyme-linked immunosorbent assay or a PEPvIII-Dynabead (Invitrogen, Carlsbad, CA) assay, as described previously.
20
Immunohistochemistry (IHC) for EGFRvIII was performed on paraffinembedded tissue, as previously described.
7,21 IHC was performed in a Clinical Laboratory Improvement Amendments-certified laboratory using compliant techniques.
Matched Cohort
Patients in the matched cohort selected for PFS and OS comparisons were all treated contemporaneously at the University of Texas M. D. Anderson Cancer Center. In the matched control cohort (n ϭ 17), all patients were adults; had EGFRvIII-expressing primary GBMs, a KPS Ն 80%, and a resection of Ͼ 95% of the original tumor volume; and had been treated with radiationandTMZ.Patientswithtumorprogressionwithin4weeksofcompleting radiation therapy were also excluded from this matched control cohort.
Methylguanine Methyltransferase Promoter Methylation Status
Samples were isolated from five sections of a representative tissue block. Following deparaffinization and proteinase K treatment, DNA was isolated from tumor tissue using a kit from Epicenter (Madison, WI). After sodium bisulfite treatment, methyl-specific polymerase chain reaction was performed as previously described. 22 A ratio of methylated-to-unmethylated peaks of Ն 1.0 was scored as methylated.
Statistical Analysis
A two-stage clinical trial design was used to differentiate between a 6-month PFS rate of 20% and 40% from the time of vaccination with ␣ and ␤ ϭ .1 on the basis of data derived from the matched cohort. If five or more of the 22 patients accrued in stage 1 were alive and free from disease progression at 6 months after vaccination, then an additional 22 patients were to be accrued during a second stage. If 11 or more of the 44 patients survived 6 months progression free from the time of vaccination, the treatment regimen was to be considered worthy of additional investigation. PFS and OS were estimated using Kaplan-Meier methods. The Cox proportional hazards model was used to compare PFS and OS of the vaccinated patients with the matched cohort; adjustments for known prognostic factors and covariates were made in the model. The study was not initially powered for these comparisons, however. Adverse events were defined according to the National Cancer Institute's Common Toxicity Criteria (Version 2.0). Frequencies were used to describe the EGFRvIII-specific antibody responses and DTH reactions. A binomial test was used to assess whether the proportion of patients with EGFRvIII IHC staining changes due to vaccination was significantly different from zero. 
RESULTS
Study Population
At both centers, all known patients with EGFRvIII-expressing newly diagnosed GBM were screened for study eligibility. Only two patients at each site refused participation despite being eligible. Twenty-one patients were enrolled and vaccinated before accrual was suspended at the end of stage 1. On retrospective quality control review, three patients were found not to meet eligibility criteria because Ͻ 95% of the tumor volume had been resected. Therefore, the primary focus of analyses reported here will involve the 18 eligible patients. Follow-up through October 2008 is reflected in this article. All but one of the patients who were vaccinated received TMZ delivered concurrently with radiotherapy 2 (Table 1) . TMZ therapy after radiation was not used in conjunction with the vaccinations. Study data are summarized in Table 2 .
Toxicity and Adverse Events
Toxicity was generally minimal (Appendix Table A1 , online only) and mostly related to injection site reactions, which never produced grade Ն 2 toxicity. However, one patient was removed from the study when a presumed severe allergic reaction (numbness and tingling in the perioral area) to the vaccine components was suspected, although a similar event occurred several weeks later when the patient had an unrelated procedure. This was still considered a serious adverse event. In addition, one patient developed asymptomatic areas of T2-signal hyperintensity that on subsequent magnetic resonance imaging scans demonstrated contrast enhancement that eventually resolved. These lesions remained hypometabolic on positron emission tomography. This reaction was deemed a grade 1 leukoencephalopathy toxicity (Appendix Table A1 and Fig 1) and resolved without treatment.
PFS
The median PFS from time of histologic diagnosis for the 18 eligible patients was 14.2 months (95% CI, 9.9 to 17.6 months; Fig 2A  and Appendix Table A2 , online only). Among the 18 eligible patients, 12 patients (67%; 95% CI, 40% to 83%) were alive and without radiographic evidence of progression 6 months after vaccination, and 17 patients (94%; 95% CI, 67% to 99%) were alive and without radiographic evidence of progression 6 months after histologic diagnosis (Appendix Table A2 ). After considering these data, we rejected the null hypothesis for the primary end point. Accrual was terminated after this interim analysis because the number of patients living progression free for more than 6 months after vaccination (n ϭ 12) exceeded the critical value associated with the hypothesis test to be conducted at the end of the second stage of the study (n Ն11).
In the matched cohort (n ϭ 17), the median PFS from histologic diagnosis was 6.3 months (95% CI, 4.1 to 9.0 months). The PFS hazard ratio (HR) comparing the matched cohort with our patients was 2.4 (95% CI, 1.2 to 5.0; P ϭ .013; Fig 2A) . Even after adjustment for age and KPS, the PFS of vaccinated patients remained significantly greater than that observed in the TMZ-treated matched control group (HR, 2.2; 95% CI, 1.0 to 4.8; P ϭ .041). Inferences were not affected by the exclusion of the three ineligible patients.
Survival Time
The median OS from time of histologic diagnosis for the 18 eligible patients was 26.0 months (95% CI, 21.0 to 47.7 months). Among the 18 eligible patients, 94% (95% CI, 67% to 99%) were alive 12 months after vaccination and 94% (95% CI, 67% to 99%) were alive at 12 months after histologic diagnosis (Fig 2B and Appendix  Table A2 ). In the matched cohort (n ϭ 17), time from histologic diagnosis to the median OS was 15.0 months (95% CI, 11.4 to 19.7 months). After adjustment for age and KPS, the survival of vaccinated patients was significantly better than that observed in a TMZ-treated matched control group (HR, 5.1; 95% CI, 1.9 to 13.9; P ϭ .001). Inferences were not affected by the exclusion of the three ineligible patients.
IHC Analysis of EGFRvIII Expression
Among recurrent tumors from which pathologic material was obtained (n ϭ 11), all were evaluated by IHC for EGFRvIII expression. Of these 11 samples, 82% (95% CI, 48% to 97%) had lost EGFRvIII expression at recurrence (binomial test P Ͻ .001; Table 3 ; Fig 3) . Of the two patients who had positive EGFRvIII staining at recurrence, one had Ͻ 1% of cells staining for EGFRvIII.
Immune Responses
At the interim analysis when the study was terminated, 14 patients had serum samples that had been analyzed for EGFRvIII-specific humoral responses. Six (43%; 95% CI, 18% to 71%; P Ͻ .001) had evidence of a humoral response against PEPvIII. The maximum concentration of antibody that reacted against The median PFS from histologic diagnosis in the patients who had been vaccinated (n ϭ 18; solid blue line) was 14.2 months (95% CI, 9.9 to 17.6 months). Dotted blue lines show 95% CIs. Right: In the temozolomide (TMZ) -treated historical cohort (n ϭ 17; gold line), the median PFS was 6.3 months (95% CI, 4.1 to 9.0 months). The PFS of patients who had been vaccinated compares favorably with that of the TMZ-treated cohort before (P ϭ .013) and after (P ϭ .041) adjustment for age and Karnofsky performance status (KPS). (B) Overall survival (OS). Left: The median survival of patients who had been vaccinated (n ϭ 18; solid blue line) was 26.0 months (95% CI, 21.0 to 47.7 months;). Dotted blue lines show 95% CIs. Right: In the TMZ-treated historical cohort (n ϭ 17; gold line), the median survival was 15.0 months (95% CI, 11.4 to 19.7 months). The OS of patients who had been vaccinated compares favorably with that of the TMZ-treated cohort before (P ϭ .002) and after (P ϭ .001) adjustment for age and KPS. EGFRVIII, epidermal growth factor receptor variant III.
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The median OS from histologic diagnosis for the six patients who developed EGFRvIII-specific antibody responses was 47.7 months (95% CI, 20.8 to ϱ months; Fig 4) . For the eight patients who did not develop antibody responses, the OS was only 22.8 months (95% CI, 21.0 to 34.9 months). After adjustment for age, KPS, and methylguanine methyltransferase (MGMT) methylation, the OS from vaccination (P ϭ .025) and histologic diagnosis (P ϭ .025) of the patients who developed antibody responses was found to be greater than the OS for those who had not. However, these findings need to be validated prospectively in a model with a larger number of patients.
To assess patient cellular immune responses to the vaccinating antigen and endogenous antigens in vivo, DTH skin tests were performed with PEPvIII and recall antigens. All patients showed no response to PEPvIII before vaccination. After vaccination, three (18%; 95% CI, 4% to 43%; binomial proportions P Ͻ .001) of 17 showed a positive DTH response to PEPvIII after vaccination.
The median OS from histologic diagnosis for the three patients who developed PEPvIII-specific DTH responses had not been reached at 50 months follow-up. For the 14 patients who did not develop DTH responses to PEPvIII, the OS was 23.1 months (95% CI, 21.0 to 44.1 months). Although the number of patients who developed PEPvIII DTH responses was small, the patients did have a significantly longer PFS and OS from vaccination and histologic diagnosis (P ϭ .03). Conversely, DTH responses to recall antigens did not have a significant effect on PFS from vaccination (P ϭ .81) or histologic diagnosis (P ϭ .88) or on OS from vaccination (P ϭ .58) or histologic diagnosis (P ϭ .61). These small patient numbers, however, preclude meaningful adjustment for known prognostic factors such as age, KPS, and MGMT methylation.
MGMT Methylation
Because almost all of our study patients were treated with concurrent TMZ during radiotherapy, an unintentional study bias may have been introduced by selecting patients with GBM that possessed the capacity for MGMT methylation, which compromises DNA repair and is associated with longer survival in patients with GBM who receive alkylating agents such as TMZ. 22 Of the patients from whom tumor tissue was obtained for MGMT testing (n ϭ 13), seven (54%) had MGMT methylation, which is a slightly higher proportion than previously reported. 22 However, the PFS and OS from either histologic diagnosis or vaccination is actually unexpectedly longer in our study for patients with unmethylated MGMT. This does not reach statistical significance in unadjusted univariate analyses but when adjusted for age and KPS, patients with unmethylated MGMT had a significantly longer PFS from vaccination (HR, 0.17; 95% CI, 0.032 to 0.90; P ϭ .037) and histologic diagnosis (HR, 0.17; 95% CI, 0.032 to 0.90; P ϭ .037) than patients with methylated MGMT who were treated with TMZ. There was also a trend for these patients to have a longer OS from vaccination (P ϭ .062) and histologic diagnosis (P ϭ .062). These data are summarized in Appendix Figure A1 and Appendix Table A3 (online only). A larger number of patients is needed, however, to validate these observations.
DISCUSSION
Our study results demonstrate that vaccinating patients who have newly diagnosed EGFRvIII-positive GBM with a peptide containing an EGFRvIII-specific epitope is safe, induces specific immunity against EGFRvIII, and is associated with the elimination of EGFRvIII-expressing cells at recurrence. This observation that an EGFRvIII-targeted vaccine is capable of potentially eliminating EGFRvIII-expressing tumor cells in the majority of patients is an intriguing finding and consistent with what we found in our preclinical studies in mice.
18 It suggests that the immunologic privilege of the brain may not be absolute in this context as well. It is difficult to differentiate between elimination of a specific population of tumor cells expressing EGFRvIII and a downregulation of the expression of the mutated tyrosine kinase, however. Recurrent tumors in these patients continue to express the wild-type EGFR protein. This raises the possibility that intramolecular cross-priming that might induce immune responses against wild-type EGFR may be attenuated.
We also found that patients with GBM who had received the PEPvIII-KLH vaccine had significantly longer OS than a contemporaneously treated cohort matched for eligibility criteria and treatment, and they compare favorably with recently published trials evaluating other patient cohorts treated with carmustine polymers (13.7 months) 23 or serial TMZ cycles (14.6 months). 2 Although the median OS time observed in this study is encouraging, it may not be different from an untreated population or from that reported in other recent studies using different immunotherapy approaches. [24] [25] [26] [27] [28] Although nearly consecutive patients with EGFRvIII-expressing GBM were enrolled at two different centers during this trial, the small sample size and restricted eligibility criteria, although chosen to optimize the identification of an immune response, led to some bias that cannot be adequately addressed despite our attempts to select an adequate matched control population. Thus, although these data suggest that vaccination with PEPvIII-KLH may improve PFS and OS in this population, definitive evidence of efficacy will require a blinded, placebo-controlled, randomized phase III study, which is currently in the planning stages.
Our finding that vaccinated patients with an unmethylated MGMT promoter, which usually confers resistance to TMZ, 22 actually had a longer PFS and OS than those patients with methylated MGMT raises the possibility that EGFRvIII-targeted vaccination may be an effective alternative for those patients and mandates that phase III trials of this vaccine approach will need to stratify patients for this variable. Although unexpected, this finding is consistent with the observation by Murat et al 29 that EGFR signaling, which would be induced in EGFRvIII-expressing tumor cells, confers resistance to TMZ and predicts a poor outcome after standard therapy. Although this study demonstrates the possible benefits of vaccination with a peptide that contains a tumor-specific epitope, there remain a number of issues that must be addressed to optimize this therapeutic modality. While one distinct advantage of our approach is 
